162 related articles for article (PubMed ID: 37343207)
21. Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
Mathew Thomas V; Grivas P; Agarwal N
Med; 2024 Feb; 5(2):109-111. PubMed ID: 38340704
[TBL] [Abstract][Full Text] [Related]
22. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Benjamin DJ; Hsu R
Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
[TBL] [Abstract][Full Text] [Related]
23. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Song Y; Yang L; Zhou A; Chi Y; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
[TBL] [Abstract][Full Text] [Related]
24. [First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced or metastatic urothelial cell carcinoma (JASINT-1 - AB 38/11) of AUO].
Rexer H
Urologe A; 2011 Aug; 50(8):974-6. PubMed ID: 21779884
[No Abstract] [Full Text] [Related]
25. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
26. Erdafitinib exerts the anticancer effect on urothelial carcinoma
Jin YY; Tong SQ; Tong M
Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
28. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Sternberg CN; Skoneczna IA; Castellano D; Theodore C; Blais N; Voog E; Bellmunt J; Peters F; Le-Guennec S; Cerbone L; Risse ML; Machiels JP
Oncology; 2013; 85(4):208-15. PubMed ID: 24080920
[TBL] [Abstract][Full Text] [Related]
29. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
[TBL] [Abstract][Full Text] [Related]
30. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Vogelzang NJ
J Clin Oncol; 2013 Feb; 31(6):670-5. PubMed ID: 23341524
[TBL] [Abstract][Full Text] [Related]
33. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
[TBL] [Abstract][Full Text] [Related]
34. Updates and novel treatments in urothelial carcinoma.
Hanna KS
J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y
Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045
[TBL] [Abstract][Full Text] [Related]
37. Meningeal carcinomatosis from transitional cell carcinoma of the bladder.
Eng C; Cunningham D; Quade BJ; Schwamm L; Kantoff PW; Skarin AT
Cancer; 1993 Jul; 72(2):553-7. PubMed ID: 8319186
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.
Albers P; Siener R; Härtlein M; Fallahi M; Haeutle D; Perabo FG; Steiner G; Blatter J; Müller SC;
Onkologie; 2002 Feb; 25(1):47-52. PubMed ID: 11893883
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
